gastric (stomach) cancer

Cancer prevention drug also disables H. pylori bacterium

A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.

Probing H. pylori cancer protein

Understanding how a bacterial protein that influences the risk of stomach cancer is produced could guide new strategies for treatment.

Toxin floats on lipid rafts

The bacterium H. pylori is a leading cause of stomach cancer, and Vanderbilt researchers are studying how one of its toxins gets into cells.

x-ray of stomach

Early drivers of gastric cancer

Using bioinformatics approaches, Vanderbilt investigators have identified gene expression networks that are deregulated in mouse and human stomach cancers.

Study seeks to reverse precancerous stomach lesions

Vanderbilt University Medical Center cancer researcher James Goldenring, M.D., Ph.D., has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New York, to begin clinical trials of a potential approach for reversing precancerous stomach lesions.

New target for chronic infection

An enzyme in macrophage immune cells may be a good target for treating chronic infections, Vanderbilt researchers have discovered.

1 2 3 4